XTX202 in Patients With Advanced Solid Tumors
NCT05052268 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 95
Last updated 2025-05-07
Summary
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors
Conditions
- Advanced Solid Tumor
Interventions
- DRUG
-
XTX202
XTX202 Monotherapy
Sponsors & Collaborators
-
Xilio Development, Inc.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-01-18
- Primary Completion
- 2025-03-22
- Completion
- 2025-03-25
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
First In Human Study of CX-2051 in Advanced Solid Tumors
NCT06265688 ·Status: RECRUITING ·Phase: PHASE1
-
Study of 23ME-01473 in Patients With Advanced Solid Malignancies
NCT06290388 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
NCT03517488 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
NCT00813384 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
NCT06707610 ·Status: RECRUITING ·Phase: PHASE1
-
Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT05474859 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
NCT01723020 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of DXC014 in Patients With Advanced Solid Tumors.
NCT07177937 ·Status: RECRUITING ·Phase: PHASE1
-
Study of ASTX029 in Subjects With Advanced Solid Tumors
NCT03520075 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
NCT06224855 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of SKLB1028 in Patients With Advanced Solid Tumor
NCT05072522 ·Status: UNKNOWN ·Phase: PHASE1
-
PTC596 in Patients With Advanced Solid Tumors
NCT02404480 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
NCT01049893 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors
NCT05650242 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors
NCT00104286 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
NCT04106492 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
NCT05103046 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of DM002 in Patients With Advanced Solid Tumors
NCT06751329 ·Status: RECRUITING ·Phase: PHASE1
-
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
NCT02503423 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors
NCT04746612 ·Status: TERMINATED ·Phase: PHASE1
-
Administration of BIIB028 to Subjects With Solid Tumors
NCT00725933 ·Status: COMPLETED ·Phase: PHASE1
-
SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
NCT00121290 ·Status: COMPLETED ·Phase: PHASE1
-
PTX-35 in Patients With Advanced Solid Tumors
NCT04430348 ·Status: TERMINATED ·Phase: PHASE1
-
Phase I Study in Patients With Solid Tumours
NCT00496028 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of AMG 337 in Subjects With Advanced Solid Tumors
NCT01253707 ·Status: COMPLETED ·Phase: PHASE1